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Abstract. Prolactin (PRL)-secreting pituitary adenomas are
the most common functioning pituitary tumors. Medical
treatment with dopamine agonists is the therapy of choice
for macroprolactinomas ($10 mm). Withdrawal of bro-
mocriptine after weeks or months of uninterrupted therapy
has been associated with rapid tumor re-expansion as evi-
denced by x-ray and CT scanning of the pituitary region. We
report a patient with a giant macroprolactinoma who had a
dramatic response to bromocriptine (tumor volume shrink-
age of 53% within a month) but rapid re-expansion to its
original dimensions one week after discontinuation of bro-
mocriptine. To our knowledge, this is the first time that the
rapid shrinkage/re-expansion of a macroprolactinoma has
been documented with serial MRI scans.
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Introduction
Prolactin (PRL)-secreting pituitary adenomas account
for 60% of all functioning-pituitary tumors. Men and
postmenopausal women who harbor macroprolacti-
nomas ($10 mm) frequently come to medical attention
with symptoms of mass effect such as visual distur-
bance or hypopituitarism. Irrespective of the size,
these tumors are treated medically with dopamine
agonists [1]. Transsphenoidal surgery [2] and radio-
therapy [3] are secondary options reserved for the pa-
tients who are resistant to dopamine agonists or who
do not tolerate them. Bromocriptine and cabergoline
are the only two dopamine agonists approved in the
United States for the treatment of prolactinomas [4],
although pergolide is a very effective alternative for
men and postmenopausal women [5]. These medica-
tions should probably be taken indefinitely to maintain
clinical, hormonal and radiological control of the tumor
[6]. Although withdrawal of bromocriptine has been
previously shown to cause tumor re-expansion [7],
documentation of significant initial tumor shrinkage,
re-enlargement after bromocriptine discontinuation,
and subsequent contraction after bromocriptine rein-
stitution has not been investigated with newer imaging
techniques. We report a patient with dramatic increase
in tumor volume to its original size after early bro-
mocriptine discontinuation as evaluated with serial
MRI scans.
Case Report
A 26-yr-old man with new onset throbbing headaches
presented to the emergency room on July 7, 1999 com-
plaining of loss of vision in the left eye. He immediately
underwent a pituitary MRI that revealed a giant pitui-
tary tumor (vertical diameter 5.5 cm, lateral diameter
5.5 cm, and anteroposterior diameter 5.2 cm) with su-
prasellar extension and compression of the optic chi-
asm (Fig. 1a). Serum PRL level was markedly elevated
at 18,494 ng/ml, testosterone was low at 1.1 ng/ml, and
random cortisol was normal at 18 ug/dl. Formal visual
testing was not performed at that time. He was placed
on bromocriptine 2.5 mg twice daily with rapid amelio-
ration of his headaches but persistence of his visual
abnormality. However, he experienced significant side
effects, including postural dizziness and nausea. One
month later (August 7, 1999) a repeat pituitary MRI
showed that the tumor volume had decreased by 53%
(vertical diameter 3.0 cm, lateral diameter 5.5 cm, and
anteroposterior diameter 4.5 cm) and that the pressure
on the optic chiasm had been relieved (Fig. 1b). Imme-
diately after that, the patient discontinued the bro-
mocriptine on his own and several days later his head-
aches recurred. He underwent another MRI one week
after discontinuation of bromocriptine. The tumor had
re-expanded to its original dimensions (Fig. 1c), and at
that time PRL was 5,583 ng/ml. Reinstitution of his
previous dose of bromocriptine resulted in rapid disap-
pearance of his headaches but not change in his visual
abnormality. Six weeks later he reported increase in
libido, improvement in quality of erections and facial
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acne. He had bilateral galactorrhea on expression. For-
mal visual field study revealed complete left temporal
hemianopsia. PRL level decreased significantly to 319
ng/ml, testosterone was low at 0.66 ng/ml, and FT4 was
normal at 1.07 ng/dl. Despite his excellent response to
bromocriptine, he was switched to pergolide 0.1 mg
twice daily because of side effects with the former. He
returned 4 months later for follow up when galactor-
rhea had disappeared but the left temporal hemianop-
sia was unchanged. PRL level continued to decline but
was still above the normal range at 90.5 ng/ml. Testos-
terone level was still low at 0.59 ng/ml. A new pituitary
MRI at that time showed additional tumor shrinkage
(Fig. 2).
Discussion
We have described a young man with a short history of
symptoms related to pituitary mass effect due to a
macroprolactinoma and his clinical, hormonal, and ra-
diological course after his voluntary discontinuation of
bromocriptine. Withdrawal of bromocriptine resulted
in re-expansion of the tumor to its original size within
a week. Reinstitution of dopamine agonists produced
significant tumor shrinkage.
Bromocriptine is a semisynthetic ergot alkaloid that
normalized PRL levels in 80–90% and shrinks tumor
size in more than 70% of patients with prolactinomas
[8]. The time course of tumor shrinkage is variable.
Some patients have improvement in visual fields defect
within 24 to 72 hours or demonstrate significant reduc-
tion in tumor size within a week. Others have more
delayed responses, but usually achieve the maximal
tumor shrinkage during the first 6 months of therapy.
Progressive decrease in adenoma size may continue for
over a year [6]. Our patient initially responded ex-
tremely well to bromocriptine with 53%-tumor volume
shrinkage within a month, but experienced significant
side effects with  subsequent discontinuation of  this
medication.
The mechanism of action of bromocriptine in tumor
shrinkage and PRL normalization is complex [9]. In
vitro studies have shown that bromocriptine reduces
PRL and DNA synthesis, PRL mRNA levels, cell mul-
tiplication, and tumor growth [10,11] Studies with
DNA flow cytometry have shown that low doses of
bromocriptine produce increase in the relative number
of cells in the S phase but decrease of those in the G1
phase, while higher doses cause inhibition of PRL syn-
Fig. 1. Coronal gadolinium-enhanced T1-weighted pituitary magnetic resonance images before (a) and after one month (b) of bro-
mocriptine administration, and one week after bromocriptine discontinuation (c). Fig. 1a shows a 5.5 3 5.5 3 5.2-cm sellar mass with
parasellar and suprasellar extension and compression of the optic chiasm. The mass has also cystic components and a small hemor-
rhagic area. Fig. 1b shows significant volume tumor shrinkage with complete decompression of the optic chiasm. Fig. 1c demonstrates
complete re-expansion of the macroprolactinoma with compression of the optic chiasm.
Fig. 2. Coronal gadolinium-enhanced T1-weighted pituitary
magnetic resonance image after 5 months of pergolide therapy.
Significant tumor shrinkage is maintained and the optic chi-
asm is fully decompressed.
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thesis and cell division [12]. Bromocriptine initially re-
duces the number of exocytosis and PRL secretory
granules, suggesting inhibition of PRL release as the
rapid mechanism of action [13,14]. However, the most
important mechanism of tumor shrinkage is reduction
in the size of lactotroph adenomatous cells due to re-
gression of rough endoplasmic reticulum and Golgi ap-
paratus with subsequent cessation of PRL synthesis
[11,15–17]. With chronic bromocriptine administration,
lactotroph tumorous cells show fragmentation of rough
endoplasmic reticula and cytoplasm, macrophage infil-
tration, aggregation of nuclear chromatin, and deposits
of  collagen between  cells  [18,19]. Finally, prolonged
administration of bromocriptine may also exert an an-
timitotic effect on some prolactinomas [20].
Withdrawal of bromocriptine or other dopamine
agonists in the setting of a macroprolactinoma is usu-
ally followed by PRL increase and/or tumor enlarge-
ment. In three patients with macroprolactinomas who
had significant  tumor  shrinkage, bromocriptine was
held with subsequent   PRL elevation and tumor
growth as soon as 5 days later as evidenced by CT
scanning [16]. Withdrawal of bromocriptine for 6 days
after one year of uninterrupted therapy in a woman
with a macroprolactinoma was followed by PRL in-
crease and tumor re-expansion by CT scanning [21].
Another patient with a large prolactinoma who pre-
sented with bilateral temporal hemianopsia was placed
on bromocriptine with complete resolution of visual
abnormalities and PRL normalization. A repeat CT
scan a year later showed a partially empty sella. Within
2 weeks of bromocriptine discontinuation, tumor re-ex-
panded and bitemporal hemianopsia recurred [7].
Longer therapy with dopamine agonists may also be
accompanied by PRL elevation after withdrawal, al-
though not always by tumor enlargement. After 1.5 to
7 years on bromocriptine or pergolide, 14/15 patients
had increase in PRL levels after stopping these medi-
cations, but only 1/15 had tumor enlargement after a 5
to 39-week follow up [22]. Similarly, discontinuation of
bromocriptine after 3.5 to 7 years of therapy, led to
PRL elevation in 11/12 patients with macroprolacti-
nomas but tumor re-expansion in only 1/12 [23]. Wang
et al. reported a patient with a macroprolactinoma who
was on bromocriptine for 10 years and the PRL was
normal and tumor stable two years after drug with-
drawal [24]. In the long-term, dopamine agonists can
be reduced to their lowest effective dose that main-
tains PRL level within the normal range [25]. Our pa-
tient had a dramatic tumor enlargement after discon-
tinuation of bromocriptine for one week. To our
knowledge, this is the first demonstration of rapid
PRL-secreting pituitary tumor re-expansion after bro-
mocriptine discontinuation documented by MRI scan-
ning.
We conclude that patients with macroprolactinomas
who have responded to dopamine agonists should be
warned about the possibility of rapid tumor re-expan-
sion after their discontinuation, particularly within the
first year of treatment.
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